NCT06469788 Testimonials and Navigation in Rheumatology
| NCT ID | NCT06469788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Rheumatologic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,170 participants |
| Start Date | 2024-12-18 |
| Primary Completion | 2027-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,170 participants in total. It began in 2024-12-18 with a primary completion date of 2027-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.
Eligibility Criteria
Inclusion Criteria: * Adults (18+ years) with known AIRD * Black race and/or Latinx ethnicity * Individuals who have not obtained the updated COVID-19 vaccine series (self-report) Exclusion Criteria: -Lack of access to phone
Contact & Investigator
Maria I Danila, MD, MSc, MSPH
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT06469788 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatologic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06469788 currently recruiting?
Yes, NCT06469788 is actively recruiting participants. Contact the research team at mawilkenson@uabmc.edu for enrollment information.
Where is the NCT06469788 trial being conducted?
This trial is being conducted at Birmingham, United States, Boston, United States, Worcester, United States.
Who is sponsoring the NCT06469788 clinical trial?
NCT06469788 is sponsored by University of Alabama at Birmingham. The principal investigator is Maria I Danila, MD, MSc, MSPH at University of Alabama at Birmingham. The trial plans to enroll 1,170 participants.